These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30427406)

  • 1. Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC).
    Tuon FF; Santos CR; Cieslinski J; Souza RM; Imamura R; Amato VS
    Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e71. PubMed ID: 30427406
    [No Abstract]   [Full Text] [Related]  

  • 2. Mucocutaneous leishmaniasis treated with liposomal amphotericin B.
    Lambertucci JR; Silva LC
    Rev Soc Bras Med Trop; 2008; 41(1):87-8. PubMed ID: 18368279
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful response to liposomal amphotericin B in mucosal leishmaniasis in glans resistant to intralesional pentavalent.
    Aguayo-Carreras P; Cuenca-Barrales C; Perez-López I; Ruiz-Villaverde R; Tercedor-Sanchez J
    Int J Dermatol; 2019 Jul; 58(7):e137-e138. PubMed ID: 30883705
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.
    Cunha MA; Leão AC; de Cassia Soler R; Lindoso JA
    Am J Trop Med Hyg; 2015 Dec; 93(6):1214-8. PubMed ID: 26483120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis.
    Crone CG; Helleberg M
    J Travel Med; 2020 Feb; 27(1):. PubMed ID: 31776570
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study.
    Santos CR; Tuon FF; Cieslinski J; de Souza RM; Imamura R; Amato VS
    PLoS One; 2019; 14(6):e0218786. PubMed ID: 31242231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis.
    Nicodemo AC; de Andrade HF; Muñoz Torres P; Amato VS
    Am J Trop Med Hyg; 2019 Aug; 101(2):402-403. PubMed ID: 31219006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
    Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review.
    Mosimann V; Neumayr A; Paris DH; Blum J
    Acta Trop; 2018 Jun; 182():246-250. PubMed ID: 29550282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucocutaneous leishmaniasis: mucosal manifestations in an endemic country.
    de Paulo LF; Rocha GF; Luisi CM; Rosa RR; Durighetto AF
    Int J Infect Dis; 2013 Nov; 17(11):e1088-9. PubMed ID: 23867693
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.
    Rodríguez Galvis MC; Pérez Franco JE; Casas Vargas MY; Ordoñez Rubiano MF
    Am J Trop Med Hyg; 2020 Feb; 102(2):274-279. PubMed ID: 31820708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B.
    Sundar S
    Lancet; 2001 Mar; 357(9258):801-2. PubMed ID: 11253992
    [No Abstract]   [Full Text] [Related]  

  • 14. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
    Rocio C; Amato VS; Camargo RA; Tuon FF; Nicodemo AC
    Trans R Soc Trop Med Hyg; 2014 Mar; 108(3):176-8. PubMed ID: 24535153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucocutaneous leishmaniasis: case report and literature review of a rare endonasal infection.
    Suqati AA; Pudszuhn A; Hofmann VM
    Pan Afr Med J; 2020; 36():292. PubMed ID: 33117486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis.
    Lamothe J
    J Small Anim Pract; 2001 Apr; 42(4):170-5. PubMed ID: 11327663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal Leishmania infantum infection.
    Richter J; Hanus I; Häussinger D; Löscher T; Harms G
    Parasitol Res; 2011 Sep; 109(3):959-62. PubMed ID: 21499751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal leishmaniasis and miltefosine.
    Tuon FF; Amato VS
    Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases.
    Sampaio SA; Castro RM; Dillon NL; Martins JE
    Int J Dermatol; 1971; 10(3):179-81. PubMed ID: 5116171
    [No Abstract]   [Full Text] [Related]  

  • 20. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?
    Amato VS; Tuon FF; Camargo RA; Souza RM; Santos CR; Nicodemo AC
    Am J Trop Med Hyg; 2011 Nov; 85(5):818-9. PubMed ID: 22049033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.